CD47 and acute myeloid leukemia: Magrolimab, first-in-class humanized anti-CD47 antibody, potently induced macrophage-mediated phagocytosis of human AML cells in vitro and in vivo, thereby eradicating leukemic cells and inducing durable remissions in patient-derived xenograft (PDX) mouse models [68].